Free tool
FAERS Monitor: Leqvio
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214012 or its brand name (Leqvio, Inclisiran Sodium). Reports on generic versions are filed under their own applications.
Reports
8,446
Serious
3,638
43% of reports
Hospitalization
857
Death reported
238
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- arthralgia908
- myalgia706
- injection site pain600
- low density lipoprotein increased529
- pain in extremity510
- drug ineffective442
- fatigue440
- pain423
- diarrhoea389
- dyspnoea375
- headache330
- rash299
- muscle spasms268
- dizziness251
- cough248
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 32 |
| 2022 | 910 |
| 2023 | 2,224 |
| 2024 | 1,909 |
| 2025 | 1,933 |
| 2026 | 1,435 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,713 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| low density lipoprotein increasedSignal | 529 | 182.6 | 167.6 | 88,867 |
| myalgiaSignal | 706 | 10.4 | 9.7 | 5,999 |
| arthralgiaSignal | 908 | 5.4 | 5.1 | 3,352 |
| injection site painSignal | 600 | 4.9 | 4.5 | 1,870 |
| pain in extremitySignal | 510 | 4.3 | 4.0 | 1,312 |
| muscle spasmsSignal | 268 | 3.6 | 3.2 | 514 |
| coughSignal | 248 | 2.2 | 1.9 | 164 |
| pain | 423 | 1.7 | 1.6 | 129 |
| rash | 299 | 1.7 | 1.5 | 89 |
| dyspnoea | 375 | 1.7 | 1.5 | 98 |
| diarrhoea | 389 | 1.5 | 1.4 | 67 |
| fatigue | 440 | 1.4 | 1.3 | 53 |
| headache | 330 | 1.3 | 1.2 | 25 |
| dizziness | 251 | 1.3 | 1.1 | 13 |
| drug ineffective | 442 | 0.8 | 0.8 | 15 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.